Landscape Capital Management L.L.C. Sells 1,846 Shares of Zoetis Inc. $ZTS

Key Points

• Landscape Capital Management L.L.C. has reduced its stake in Zoetis Inc. by 15.2%, selling 1,846 shares, and now holds 10,311 shares valued at approximately $1.7 million.
• Zoetis reported earnings of $1.76 EPS for the last quarter, surpassing analyst expectations, with revenue reaching $2.46 billion, marking a 4.2% increase from the previous year.
• Recent analyst ratings have been mixed, with Leerink Partners downgrading Zoetis to "market perform" and adjusting their price target down to $155.00 from $180.00.

Landscape Capital Management L.L.C. lessened its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 15.2% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 10,311 shares of the company's stock after selling 1,846 shares during the quarter. Landscape Capital Management L.L.C.'s holdings in Zoetis were worth $1,698,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in ZTS. Brighton Jones LLC raised its holdings in shares of Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock valued at $754,000 after acquiring an additional 2,978 shares in the last quarter. Lido Advisors LLC increased its holdings in shares of Zoetis by 79.5% during the fourth quarter. Lido Advisors LLC now owns 20,375 shares of the company's stock valued at $3,320,000 after acquiring an additional 9,021 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of Zoetis by 11.7% during the fourth quarter. AQR Capital Management LLC now owns 293,658 shares of the company's stock valued at $47,846,000 after acquiring an additional 30,726 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Zoetis during the fourth quarter valued at $308,000. Finally, Utah Retirement Systems boosted its position in shares of Zoetis by 0.3% during the fourth quarter. Utah Retirement Systems now owns 75,795 shares of the company's stock valued at $12,349,000 after buying an additional 200 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Price Performance

ZTS traded down $3.59 on Tuesday, hitting $152.81. 1,575,150 shares of the company's stock traded hands, compared to its average volume of 3,063,276. The company's 50 day simple moving average is $153.49 and its 200-day simple moving average is $157.85. The firm has a market cap of $67.72 billion, a price-to-earnings ratio of 26.30, a P/E/G ratio of 2.51 and a beta of 0.88. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. The company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm's quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter last year, the company earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on ZTS shares. Piper Sandler increased their price objective on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research report on Monday, August 11th. Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and dropped their target price for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, UBS Group lowered their price objective on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $202.43.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.